

## LIPID-BASED DRUG DELIVERY SYSTEMS FOR POORLY WATER-SOLUBLE DRUGS: A REVIEW

\*<sup>1</sup>Hirkani Yuvraj Pawar, <sup>2</sup>Chavala Vasanthi, <sup>3</sup>Ms. Swati Sanjay Mhaske,

<sup>4</sup>Prof (Dr) Gourishankar Birtia, <sup>5</sup>Neel Thanki, <sup>6</sup>Suyog Pandharinath

<sup>1</sup>Assistant Professor, Bharathi Vidyapeeth College of Pharmacy, Palus.

<sup>2</sup>Associate Professor, College of Pharmacy Victoria.

<sup>3</sup>M Pharm Student, VPS College of Pharmacy.

<sup>4</sup>Associate Professor, Sanaka Educational Trust's Group of Institutions.

<sup>5</sup>Student, Government College of Pharmacy, Ratnagiri.

<sup>6</sup>HOD, Kydsects College of Pharmacy, Sakegaon.

Article Received on 16 April 2026,  
Article Revised on 06 May 2026,  
Article Published on 16 May 2026,

<https://doi.org/10.5281/zenodo.20200891>

### \*Corresponding Author

**Hirkani Yuvraj Pawar**

Assistant Professor, Bharathi  
Vidyapeeth College of Pharmacy,  
Palus.



**How to cite this Article:** \*<sup>1</sup>Hirkani Yuvraj Pawar, <sup>2</sup>Chavala Vasanthi, <sup>3</sup>Ms. Swati Sanjay Mhaske, <sup>4</sup>Prof (Dr) Gourishankar Birtia, <sup>5</sup>Neel Thanki, <sup>6</sup>Suyog Pandharinath. (2026). Lipid-Based Drug Delivery Systems For Poorly Water-Soluble Drugs: A Review. World Journal of Pharmaceutical Research, 15(10), 374-399.

This work is licensed under Creative Commons Attribution 4.0 International license.

### ABSTRACT

Poor water solubility is still one of the toughest problems in drug development today. It really limits how effective a lot of new drugs can be. Around 40–70% of new chemical compounds just don't dissolve well in water. So, when you take them by mouth, they don't break down enough in your gut, which means people absorb less of the drug, and the results can be unpredictable. This issue is especially tough for drugs in Biopharmaceutics Classification System (BCS) Class II and Class IV—these are the ones where solubility basically controls how much your body absorbs. Because of all this, finding ways to improve how well drugs dissolve is a huge focus in pharmaceutical research. That's where lipid-based drug delivery systems, or LBDDS, come in. In the last few years, these systems have gotten a lot of attention. They use different combinations of lipids, surfactants, and solvents to help put

drugs into lipid matrices, which bumps up their solubility. Once taken, these systems can create tiny emulsions or dispersions in the gut, making way more surface area for the drug to get absorbed. On top of that, LBDDS can help drugs cross cell membranes better and even encourage lymphatic uptake, letting some drugs skip right past the liver's first-pass

metabolism. That often boosts how much of the drug reaches the bloodstream. There are a bunch of types of LBDDS: liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), self-emulsifying drug delivery systems (SEDDS), and nanoemulsions. Each kind has its own set of perks. SEDDS, for example, make micro- or nano-emulsions super quickly in the gut. SLNs and NLCs do a great job controlling how fast the drug releases and keeping it stable. Liposomes stand out for being biocompatible and versatile—they can carry both water-soluble and fat-soluble drugs. LBDDS work in several ways to help the body absorb drugs better. They improve how much of the drug dissolves in the gut, speed up the dissolution rate, make the gut wall more permeable, block efflux transporters like P-glycoprotein, and tap into lymphatic transport. Put together, these mechanisms lead to better drug levels in the bloodstream and, hopefully, better therapeutic effects. Still, lipid-based delivery isn't without its headaches. There can be stability issues, toxicity (if you need a lot of surfactants), and a real challenge scaling up production. But researchers keep finding new solutions by choosing smarter lipids, tweaking formulations, and using nanotechnology. This review will dig into all things LBDDS: how they're classified, how they're made, how they make drugs more available in the body, their pros and cons, and the latest breakthroughs. With more and more poorly soluble drugs in development, LBDDS have become a vital part of modern pharmaceutical R&D.


**KEYWORDS:** Lipid-based drug delivery, bioavailability, poorly soluble drugs, SEDDS, liposomes, nanoparticles.

## 1. INTRODUCTION

Let's be honest—poor water solubility still trips up a ton of promising new drugs. It's a huge hurdle in drug development, and it limits what these medicines can actually do. About 40–70% of the new compounds just won't dissolve in water. So when someone takes them by mouth, the drug doesn't break down much in the gut, meaning absorption drops and the results turn unpredictable. This hits especially hard with drugs in BCS Class II and Class IV, where solubility pretty much makes or breaks absorption.<sup>[1]</sup>

Because of all this, improving how well medicines dissolve is a big target for pharmaceutical researchers. Lipid-based drug delivery systems—LBDDS—are right at the center of this effort. Over the past few years, scientists have started paying real attention to these systems. They use blends of lipids, surfactants, and solvents to mix the drug into a lipid matrix, which pushes the solubility way up. When you take these drugs, LBDDS create tiny emulsions or

dispersions in the gut. This gives the drug more surface area, so your body absorbs it better. Plus, LBDDS help drugs get across cell membranes more easily and boost lymphatic absorption, letting some drugs dodge the liver's first-pass metabolism. That usually means more of the drug actually gets into your bloodstream.



**Figure 1: Problem of Poor Water Solubility.**

LBDDS isn't just one thing—there are all sorts: liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), self-emulsifying drug delivery systems (SEDDS), and nanoemulsions. Every type does something a bit different. SEDDS, for example, whip up micro- or nano-emulsions in the gut pretty fast. SLNs and NLCs help control how quickly the drug gets released and keep it more stable. Liposomes are super biocompatible and versatile—they can carry both water- and fat-soluble drugs. These systems work in a bunch of ways. They improve how much the drug dissolves in the gut, speed up the dissolution rate, make the gut wall easier to pass through, block efflux transporters like P-glycoprotein, and enable lymphatic transport. All together, this gives you higher drug levels in your bloodstream and—hopefully—better results.<sup>[2]</sup>

But let's not pretend it's all smooth sailing. Lipid-based delivery can be tricky. You run into stability issues, possible toxicity if you need lots of surfactants, and things get complicated when it's time to scale up production. Still, researchers keep coming up with creative fixes:

picking smarter lipids, tweaking formulations, and leveraging nanotechnology. This review is going to go deep into LBDDS—how they’re classified, made, how they boost drug availability, their ups and downs, and the latest advances. With so many poorly soluble drugs in the pipeline, LBDDS are turning into a staple of modern pharmaceutical research.<sup>[3]</sup>

## 2. Biopharmaceutics Classification System (BCS)

Let’s face it—poor water solubility keeps messing up the chances of a lot of new drugs. It’s still one of the biggest headaches in drug development, and it really limits what those medicines can actually do. Right now, somewhere between 40 and 70% of new drug candidates just won’t dissolve well in water. So if someone swallows one of those drugs, not much dissolves in the digestive tract, which drops absorption and makes the results kind of unpredictable. This problem is even worse for drugs in BCS Class II and IV, where solubility is basically the deciding factor for absorption.<sup>[4]</sup>

That’s why pharmaceutical researchers are laser-focused on making medicines dissolve better. Lipid-based drug delivery systems—LBDDS—are at the heart of this push. Lately, scientists have started to zero in on these systems. The idea is pretty clever: combine lipids, surfactants, and solvents to load the drug into a lipid matrix, and suddenly, the drug’s solubility jumps. When you take one of these drugs, LBDDS form tiny emulsions or dispersions right in your gut. That means more surface area for absorption, so your body can actually use more of the drug. Even better, LBDDS help drugs slip across cell membranes and ramp up lymphatic absorption, letting some of the medicine sidestep the liver’s first-pass effect. So, more drug survives and makes it into your bloodstream.<sup>[5]</sup>

**Table 1: Lipid formulation classification system: characteristic features, advantages, and disadvantages.**

Formulation Type	Material	Characteristics	Advantages	Disadvantages
Type I	Oils without surfactants (e.g., tri-, di-, and monoglycerides)	Nondispersing; requires digestion	Generally recognized as safe (GRAS); simple; excellent capsule compatibility	Poor solvent capacity unless drug is highly lipophilic
Type II	Oils and water-insoluble surfactants	SEDDS formed without water-soluble components	Unlikely to lose solvent capacity on	Turbid o/w dispersion (particle size

			dispersion	0.25–2 μm)
<b>Type III</b>	Oils, surfactants, and cosolvents (both water-insoluble and water-soluble excipients)	SEDDS/SMEDDS formed with water-soluble components	Clear or almost clear dispersion; improved drug absorption without digestion	Possible loss of solvent capacity on dispersion; less easily digested
<b>Type IV</b>	Water-soluble surfactants and cosolvents	Formulation disperses to form micellar solution	Good solvent capacity for many drugs	Likely loss of solvent capacity on dispersion; may not be digestible

There's not just one kind of LBDDS—there's a whole lineup: liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), self-emulsifying drug delivery systems (SEDSS), and nanoemulsions. Each type brings something different to the table. Take SEDSS, for example—they create micro- or nano-emulsions in the gut pretty much instantly. SLNs and NLCs give better control over how fast the drug gets released and make things more stable. Liposomes are crowd-pleasers—they're super biocompatible and can carry both water- and fat-loving drugs.<sup>[6]</sup>

These systems pull off several tricks at once. They boost how much drug dissolves in the gut, speed up dissolution, help the drug cross the gut wall, block pesky efflux transporters like P-glycoprotein, and kickstart lymphatic transport. All together, you get higher drug levels in your blood—and, fingers crossed, better outcomes. But it's not all easy. Lipid-based delivery comes with its own set of challenges. Sometimes the systems aren't stable, sometimes surfactants get toxic if you need a lot, and manufacturing can turn into a puzzle when you try to scale things up. But researchers aren't backing down—they're finding new lipids, tweaking the formulations, and turning to nanotech to smooth out the bumps.<sup>[7]</sup>


This review digs into LBDDS—how they're classified, how they're made, how they increase drug bioavailability, their big strengths and stubborn weaknesses, plus the latest innovations. With so many drugs struggling to dissolve, LBDDS are quickly becoming a mainstay in pharmaceutical research. LBDDS are particularly beneficial for Class II and Class IV drugs.

### 3. Lipid-Based Drug Delivery Systems (LBDDS): Overview

Lipid-based drug delivery systems, or LBDDS, really step up when it comes to getting tricky, poorly water-soluble drugs into your body. Think of them as clever blends of lipids and other

helpers that keep those lipophilic drugs dissolved and ready for action as they move through your gut. What's especially smart about these systems is how they help drugs spread out and form tiny structures—like emulsions, micelles, or vesicles—that your body is good at absorbing.<sup>[8]</sup>

One thing I like about LBDDS is they mimic how your body naturally digests fats. When you swallow these formulations, your pancreatic enzymes break them down, releasing monoglycerides and free fatty acids. These digestion products don't just hang around; they get busy mixing with bile salts and phospholipids to form mixed micelles, which are basically mini vehicles that transport the drug right across your intestinal lining. Plus, they have a knack for helping certain drugs bypass the liver on their way into your bloodstream, which means more of the drug ends up where it's needed.



**Figure 2: Mechanism of LBDDS in GI Tract.**

LBDDS comes in all shapes and sizes—self-emulsifying systems (SEDDS), nanoemulsions, liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs). The way you build these systems depends mainly on the drug's properties, how you want it released, and how you're going to give it to someone.<sup>[9]</sup>

**Now, onto the parts that make LBDDS tick**

**Lipids (Oils):** These are the workhorses, the main reason these systems can dissolve lipophilic drugs. Lipids also help your body absorb the drug by stimulating bile production and boosting lymphatic transport. You'll see two main types: long-chain triglycerides (like soybean and olive oil), and medium-chain triglycerides (like caprylic/capric oils). MCTs are often chosen for their better ability to dissolve drugs and quicker breakdown, but LCTs are tops for moving drugs through the lymphatic system.<sup>[10]</sup>

**Surfactants:** These guys make things smooth. They lower the tension between oil and water, so stable emulsions can form. The non-ionic types (like the Tween and Span series) are favorites because they're safer and easier on the body. Surfactants also help drugs be absorbed by making things wetter and sometimes tweaking the gut lining to let more drug through.

**Co-surfactants:** If you want a really fine emulsion, co-surfactants step in. They make the interfacial film more flexible and stable, often leading to a homogeneous micro- or nano-emulsion. Common co-surfactants are short-chain alcohols, like ethanol, and glycols such as propylene glycol.

**Co-solvents:** These are like the backup team, improving how well both the drug and other ingredients dissolve. They're great for keeping the drug dissolved and stopping it from clumping up when it hits your gut fluids. Polyethylene glycol (PEG), glycerol, and ethanol are standard choices. But you have to get the concentration just right—too much, and the drug could precipitate instead of staying dissolved.<sup>[11]</sup>

## 4. Classification of Lipid-Based Drug Delivery Systems

### 4.1 Liposomes

Lipid-based drug delivery systems come in a bunch of different forms, depending on what they're made of, how they're built, and how they actually deliver the drugs. Out of all these, liposomes are probably the most researched and the ones people started working with first. Their structure and functions really make them stand out.

### 4.1 Liposomes

Liposomes are like tiny bubbles—spheres made from one or more layers of phospholipids wrapping around an inner watery center. Usually, these phospholipids come from natural or

synthetic sources, like phosphatidylcholine. People often add cholesterol too, since it makes the whole structure more stable. These things are “amphiphilic,” which just means they can carry both water-loving (hydrophilic) drugs in the middle and fat-loving (lipophilic) drugs inside the lipid layers. So they’re really flexible as drug carriers.

You can find liposomes in different sizes and layers: there are small unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs), and multilamellar vesicles (MLVs). And scientists can tweak their physical and chemical properties to control how fast the drug comes out, how long they circulate in the body, and even make them home in on certain tissues. For example, when they cover liposome surfaces with polyethylene glycol (PEGylation), they get “stealth liposomes”—these last longer in the bloodstream because the body’s cleanup systems don’t spot them easily. If a drug doesn’t dissolve well in water, liposomes can boost its solubility by trapping fat-soluble molecules in the phospholipid layers, plus they keep the drug safe from being broken down inside the body. Liposomes can target drugs both passively (like slipping into tumors where blood vessels leak more easily) and actively (by attaching ligands that grab onto specific cell types).<sup>[12]</sup>

### Advantages

- **Biocompatibility and biodegradability:** Since liposomes use natural lipids, they’re generally safe and well-tolerated.
- **Encapsulate all sorts of drugs:** They work for both hydrophilic and lipophilic drugs.
- **Targeted delivery:** Scientists can design them to send drugs where they’re needed, so fewer healthy cells get hit.
- **Less toxicity:** Drugs stay wrapped up until they reach their target, protecting healthy tissues.
- **Controlled release:** Liposomes can let out their payload slowly, which improves how well the treatment works.

### Limitations

- **Instability:** Liposomes can clump together, leak their cargo, or their lipids might break down over time. Storage can be tricky.
- **Cost:** It’s expensive to make liposomes and get the ingredients.
- **Short shelf life:** They don’t always stay fresh for long periods.
- **Scaling up:** Making them in large batches with consistent quality is still a challenge.

Solid lipid nanoparticles, or SLNs, are tiny carriers—think anywhere from 50 up to 1000 nanometers across—made from solid lipids that stay solid at room and body temperatures. These lipids get stabilized using surfactants mixed in water, so the drug ends up either dispersed throughout or dissolved inside the matrix. You’ll often see lipids like glyceryl monostearate, stearic acid, or triglycerides used for SLNs. Basically, SLNs give you a modern twist on older carriers like emulsions and liposomes. You get the best parts of both, and fewer drawbacks. They really shine when it comes to boosting the bioavailability of drugs that don’t dissolve well in water—by helping to solubilize the drug and protect it from getting broken down chemically or by enzymes.<sup>[13]</sup>

So what’s good about SLNs? You can control how the drug releases, so it can last longer or release steadily. They’re more physically stable than emulsions and keep well during storage. The way the drug is wrapped up in the SLN can shield it from things like oxidation or enzymes trying to break it down. Since the lipids are ones the body likes, toxicity isn’t really a big worry. But there are some issues. The solid lipid structure is pretty rigid, so it can’t hold much drug—there’s only so much room. Sometimes the structure changes with time and the drug leaks out. Also, in storage, the formula can turn into a gel, which messes things up.<sup>[14]</sup>

**Next up:** nanostructured lipid carriers, or NLCs. These are a step up from SLNs, made to fix their flaws. NLCs mix solid and liquid lipids, which creates a matrix packed with little “imperfections.” That means more drug gets loaded in, and there’s less risk of it leaking during storage. Blending oils into the solid provides flexibility, so NLCs can take on a bigger drug load and stand up better to storage. You also still get controlled release, just like SLNs. NLCs work for a bunch of delivery methods—oral, topical, injections—you name it.<sup>[15]</sup>

**What makes NLCs special?** They can carry more drug because of those imperfections. They hold onto the drug better, so it doesn’t leak as much over time. They’re more stable and less likely to go through those annoying transitions SLNs have. Plus, they work for lots of different ways to deliver drugs.

Now, let’s talk about self-emulsifying drug delivery systems, or SEDDS. These are mixtures of oils, surfactants, and co-solvents. When they hit the gut and get gently mixed around, they form tiny oil-in-water emulsions, no need for extra energy. SEDDS are great for improving how much your body absorbs drugs that don’t dissolve well in water. They keep the drug

dissolved and ramp up the surface area for absorption. They also help push drugs into the lymphatic system and smooth out the unpredictability of absorption.<sup>[16]</sup>

**There are a couple types:** SMEDDS form microemulsions—droplets between 100–250 nanometers. SNEDDS go smaller, below 100 nm, which helps even more with absorption and stability.

**Why pick SEDDS?** You get better oral bioavailability since drugs are more easily absorbed. Making them isn't complicated and you can scale up production. Food doesn't mess with absorption as much. Also, SEDDS protect drugs from the harsh conditions inside your gut.

**Finally, there's nanoemulsions.** These are stable blends of two liquids that don't mix—usually oil and water—held together by surfactants, with droplet sizes from 20 to 200 nm. Because the droplets are so small, nanoemulsions look clear or slightly cloudy, and they don't separate or settle.

**Nanoemulsions** give you lots of surface area, which helps drugs dissolve and get absorbed faster. They're popular for delivering lipophilic drugs orally, topically, or by injection. Another perk is better targeting and more consistent absorption.

**The perks with nanoemulsions?** High surface area means quick drug release and fast absorption. They boost the bioavailability of drugs that don't dissolve easily in water. They're stable—no separation or sedimentation. Plus, you can use them for all kinds of delivery methods.

## 5. Mechanisms of Bioavailability Enhancement


Lipid-based drug delivery systems (LBDDS) make it a lot easier for your body to absorb drugs that don't dissolve well in water. They work through a mix of both chemical and biological tricks in the gut, tackling more than just solubility—they also affect drug absorption and the body's natural barriers. Here's how they get the job done:

### Better Solubilization in the Gut

The big advantage here is that LBDDS keep the drug dissolved in your digestive fluids. They do this by tucking the drug into lipid carriers, and when these lipids break down, they form monoglycerides and fatty acids. These combine with bile salts and phospholipids to create mixed micelles—basically, tiny bubbles that hold drugs. These bubbles dramatically boost how much of the drug actually dissolves, making more of it available for absorption.<sup>[17]</sup>

### Faster Dissolution

A lot of drugs just don't dissolve quickly in water, which really slows down absorption. LBDDS help by keeping drugs already dissolved or by forming tiny droplets with a big surface area. The smaller the particles, the easier and quicker the drug gets released into GI fluids, which speeds up how fast it gets absorbed.<sup>[18]</sup>



**Figure 3: Multi-Mechanism Action of LBDDS.**<sup>[19]</sup>

### Lymphatic Transport Skips First-Pass Metabolism

Here's something neat—LBDDS can send certain fatty drugs through the lymphatic system instead of the normal blood route. Drugs with high fat-solubility hop onto chylomicrons (fat carriers) formed during digestion, letting them get into the body while dodging the liver's first-crack at breaking them down. This way, more of the drug survives and gets where it needs to go.

### Blocking Efflux Transporters

Some ingredients in LBDDS, like surfactants and special lipids, can block pumps (like P-glycoprotein) that normally push drugs back into the gut and out of the body. Shutting down these pumps means more of the drug stays in your system and is actually used.

### **Boosting Intestinal Permeability**

Finally, these systems can help drugs cross the gut wall by making cell membranes more fluid or opening up the spaces between cells. Surfactants work as permeation enhancers, and products from lipid digestion can improve how easily drugs move through the barrier, too.

All these actions working together make LBDDS a powerful way to deliver drugs that usually struggle with poor solubility and tough absorption. By tackling several challenges at once, LBDDS can really change how well a drug works in the body.<sup>[20]</sup>

## **6. Formulation Considerations**

Getting lipid-based drug delivery systems (LBDDS) right comes down to how you pick and fine-tune both the ingredients and the process. The choices you make here have a huge impact: they affect how well the system dissolves the drug, stays stable, and ultimately, how much of the drug gets absorbed. Here's what really matters when you're designing one:

### **• Drug Solubility in Lipids**

You have to know how well your drug dissolves in different lipid excipients. Drugs with higher lipophilicity (those with a high log P) fit much better into these systems. Usually, you start by running screening studies to find which oils and lipid blends can actually hold the most drug. It's not just about getting the drug dissolved at first—you also need to keep it that way as it moves through the GI tract, so it doesn't just drop out and ruin absorption.<sup>[21]</sup>

### **• Picking the Right Surfactant**

Surfactants help everything mix and stay that way. Your choice mostly boils down to things like HLB (hydrophilic-lipophilic balance), toxicity, and whether the surfactant plays well with the other ingredients. Non-ionic surfactants are usually the safest bet—they're less toxic and easier on the body. But you can't just pile them in: you need enough to create a good emulsion, but not so much that you end up causing irritation.

### **• Formulation Stability**

Stability is always a headache with lipid-based systems. These formulas can fall apart physically (think phase separation, creaming, or the drug just dropping out), and the lipids can break down chemically through oxidation or hydrolysis. You can use antioxidants and choose the right packaging to slow things down, but you still need to run both long-term and faster (accelerated) stability studies to really know your product will last.

### • Droplet Size and Distribution

Droplet size isn't a minor detail—it drives how well your LBDDS works, especially if you're dealing with SEDDS or nanoemulsions. Smaller droplets mean more surface area, and that makes it easier for the drug to get out and be absorbed. If droplet sizes are all over the place, absorption and stability get unpredictable, so you want a tight distribution—a low polydispersity index. High-pressure homogenization and ultrasonication are standard ways to hit your target droplet size.<sup>[22]</sup>

### • Excipient Compatibility

Not all ingredients get along. If your drug and excipients react badly, you risk breakdown, precipitation, or a drop in effectiveness. That's why you need solid preformulation work: compatibility tests, thermal analysis, anything to be sure everything works smoothly together and doesn't compromise your system.

## 7. Evaluation Parameters

The evaluation of lipid-based drug delivery systems (LBDDS) is essential to ensure their quality, stability, and performance. A comprehensive characterization helps in understanding the physicochemical properties of the formulation and predicting its *in vivo* behavior. The key evaluation parameters are described below:

### • Particle Size Analysis

Particle size is a critical parameter influencing drug release, absorption, and stability. Smaller particle or droplet sizes provide a larger surface area, leading to enhanced dissolution and bioavailability. Particle size is commonly measured using techniques such as dynamic light scattering (DLS), laser diffraction, and electron microscopy. A narrow size distribution is desirable for uniform drug delivery.<sup>[23]</sup>

### • Zeta Potential

Zeta potential indicates the surface charge of particles and is an important indicator of physical stability. It helps predict the tendency of particles to aggregate; higher absolute values (positive or negative) generally indicate better stability due to electrostatic repulsion. Zeta potential is typically measured using electrophoretic light scattering techniques.

### • Drug Content and Encapsulation Efficiency

Drug content refers to the total amount of drug present in the formulation, while encapsulation efficiency indicates the percentage of drug successfully incorporated within the

lipid carrier. High encapsulation efficiency is desirable for effective drug delivery. These parameters are usually determined using analytical techniques such as UV spectroscopy, HPLC, or LC-MS.

#### • **In Vitro Dissolution Studies**

In vitro dissolution studies are performed to evaluate the rate and extent of drug release from the formulation. These studies simulate gastrointestinal conditions and provide insight into the release profile of the drug. Standard dissolution apparatus (USP I or II) is commonly used, and results are crucial for predicting in vivo performance and ensuring batch-to-batch consistency.

#### • **Stability Studies**

Stability studies assess the physical and chemical integrity of the formulation over time under various environmental conditions (temperature, humidity, and light). Parameters such as particle size, drug content, phase separation, and degradation products are monitored. Stability studies are conducted as per regulatory guidelines (e.g., ICH) to determine shelf life and storage conditions.<sup>[24]</sup>

#### • **In Vivo Bioavailability Studies**

In vivo studies are performed to evaluate the pharmacokinetic performance of LBDDS, including parameters such as maximum plasma concentration (C<sub>max</sub>), time to reach peak concentration (T<sub>max</sub>), and area under the curve (AUC). These studies provide direct evidence of enhanced bioavailability compared to conventional formulations. Animal models or human clinical studies are used depending on the stage of development.<sup>[25]</sup>

### **8. Advantages of LBDDS**

Lipid-based drug delivery systems (LBDDS) have a clear edge over the usual dosage forms, especially when it comes to getting poorly water-soluble drugs to actually work. Thanks to the way they're built and how they interact with the body, they boost drug delivery and treatment results in ways standard tablets just can't. Here's what sets them apart:

#### • **Better Solubility and Faster Dissolution**

Let's start with the biggest win: these systems make it much easier for lipophilic (fat-loving) drugs to dissolve. When you put drugs inside a lipid matrix, they stay solubilized. That means they don't sit around as chunks, waiting to break down. Once you take the drug, LBDDS

break into tiny emulsions or micelles. This seriously increases the surface area, so the drug dissolves faster and works more efficiently.<sup>[26]</sup>

#### • Higher Bioavailability

LBDDS really step things up by getting more of the drug into your system. They do this in a few ways — improving solubility, speeding up dissolution, boosting absorption through the gut wall, and helping the drug slip into the lymphatic system. They also avoid the liver's first-pass effect, so the drug doesn't get broken down as much before it gets to work. That leads to better therapeutic results.

#### • More Consistent Dosing

Traditional forms of hard-to-dissolve drugs are unpredictable; absorption can swing from person to person, or even dose to dose. LBDDS smooth that out. They give you a steadier release and absorption profile, so you're much more likely to get reliable effects each time. Patients are more likely to stick to their medications when results aren't all over the place.<sup>[48]</sup>

#### • Shields Drugs from Harsh Conditions

Encapsulating drugs in a lipid coating protects them from your stomach's tough environment, including powerful enzymes or acid that might otherwise break the drug down before it has a chance to do anything. The lipid matrix works as a barrier, keeping the drug intact until it's absorbed.<sup>[27]</sup>

#### • Targeted Delivery

One of the smartest moves with LBDDS is engineering them for targeted delivery. By tweaking the outer surface — adding ligands or polymers, for instance — it's possible to direct the drug straight to certain tissues or cells. This is especially useful in cancer treatment, where targeted delivery through things like the enhanced permeability and retention (EPR) effect can make a big difference. You get more of the drug where it's needed, and less where it's not, so side effects go down and treatment works better.<sup>[49]</sup>

### 9. Limitations of LBDDS

Lipid-based drug delivery systems (LBDDS) offer plenty of benefits, but they also come with headaches that can make development tricky. Not everything goes smoothly with these formulations—especially when it comes to keeping them stable, producing them at scale, and securing regulatory approval. Here's a closer look at some of the main issues.<sup>[47]</sup>

**• Stability Issues (Oxidation and Hydrolysis)**

Stability is a big one. Lipid-based formulations have trouble with both chemical and physical stability. Unsaturated fatty acids, for example, tend to break down through oxidation. The result? Rancidity and a real drop in product quality. Hydrolysis is another problem—moisture triggers the breakdown of triglycerides into fatty acids and glycerol, messing with drug potency and shortening shelf life. You might also see phase separation, particles clumping together, or the drug simply falling out of solution as it sits on the shelf. To fight back against all this, you often need antioxidants, special packaging, and tight control over storage conditions.<sup>[28]</sup>

**• High Surfactant Concentration and Toxicity**

Then there's the surfactant problem. LBDDS usually need large amounts of surfactants to keep the drug well-mixed and soluble. But cranking up the surfactant content isn't harmless. High concentrations can irritate the gut, damage biological membranes, and even cause toxicity. This limits how these drugs can be used, especially over long periods. So, picking the right kind of surfactant and dialing in just enough—without going overboard—is key.<sup>[29]</sup>

**• Scale-Up and Manufacturing Challenges**

Scaling up from lab to commercial production isn't straightforward either. What works in a small lab batch doesn't always translate to big industrial runs. You've got to think about things like making every batch the same, picking the right equipment, and keeping the process under control. Techniques like high-pressure homogenization or ultrasonication, which are great for small batches, aren't so easy to pull off efficiently on a larger scale. And keeping droplet sizes right, making sure everything's stable, and distributing the drug evenly turns into a juggling act.<sup>[30]</sup>

**• Regulatory Concerns**

Finally, there's the regulatory maze. Regulators often get nervous about these systems because they're complex and don't always behave predictably in the body. The quality of ingredients can vary, there aren't many standardized tests, and long-term safety data for some lipid ingredients can be thin. Plus, some regions don't even have clear guidelines for approving these kinds of formulations, which can slow everything down. To get through, developers need solid characterization, proof of stability, and strong safety data.<sup>[46]</sup>

In short, LBDDS show a lot of promise, but there's plenty to overcome before they make it from the lab to the clinic.

## 10. Recent Advances

In recent years, significant advancements in formulation science, nanotechnology, and computational tools have led to the development of innovative lipid-based drug delivery systems (LBDDS). These advances aim to overcome the limitations of conventional lipid formulations and further enhance drug targeting, stability, and therapeutic efficacy.<sup>[31]</sup>

### • Lipid-Polymer Hybrid Nanoparticles

Lipid-polymer hybrid nanoparticles (LPHNs) represent a novel class of delivery systems that combine the advantages of both lipid-based carriers and polymeric nanoparticles. These systems typically consist of a polymeric core surrounded by a lipid shell, providing structural integrity along with improved biocompatibility. The polymer core offers controlled and sustained drug release, while the lipid layer enhances drug solubilization and facilitates interaction with biological membranes. LPHNs have shown promising results in improving drug stability, bioavailability, and targeted delivery, particularly in cancer therapy.<sup>[32]</sup>

### • Targeted Lipid Carriers

Targeted lipid-based systems are designed to deliver drugs specifically to diseased tissues or cells, thereby minimizing systemic side effects and improving therapeutic efficiency. Targeting can be achieved through passive mechanisms, such as the enhanced permeability and retention (EPR) effect, or active mechanisms involving surface modification with ligands such as antibodies, peptides, or folic acid. These targeted systems are widely explored in the delivery of anticancer, antiviral, and gene therapies, where site-specific drug action is crucial.<sup>[45]</sup>

### • Stimuli-Responsive Lipid Systems

Stimuli-responsive (or “smart”) lipid systems are engineered to release drugs in response to specific internal or external triggers, such as pH, temperature, enzymes, light, or magnetic fields. For example, pH-sensitive liposomes can release their payload in the acidic environment of tumors or inflamed tissues. These systems enable controlled and site-specific drug release, enhancing therapeutic outcomes while reducing adverse effects. The development of such smart delivery systems represents a significant step toward personalized medicine.<sup>[33]</sup>

### • Use of Artificial Intelligence in Formulation Design

Artificial intelligence (AI) and machine learning (ML) are increasingly being applied in the design and optimization of LBDDS. AI tools can analyze large datasets to predict drug-excipient compatibility, optimize formulation composition, and forecast stability and performance. This data-driven approach reduces the time and cost associated with traditional trial-and-error methods. AI also facilitates the development of predictive models for bioavailability and pharmacokinetics, enabling more efficient and rational formulation design.<sup>[44]</sup>

## 11. Applications

Lipid-based drug delivery systems (LBDDS) have been widely applied across various therapeutic areas due to their ability to enhance solubility, improve bioavailability, and enable targeted drug delivery. These systems are particularly valuable for drugs with poor aqueous solubility and complex pharmacokinetic profiles. The major applications of LBDDS are discussed below:<sup>[34]</sup>

### • Anticancer Drugs

LBDDS have shown significant potential in the delivery of anticancer agents, many of which are highly lipophilic and exhibit poor water solubility. Drugs such as paclitaxel, docetaxel, and curcumin benefit from lipid-based formulations that enhance their solubility and stability. Liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs) are commonly used to deliver anticancer drugs. These systems can improve tumor targeting through passive mechanisms like the enhanced permeability and retention (EPR) effect or through active targeting strategies. Additionally, LBDDS help reduce systemic toxicity and improve therapeutic outcomes.<sup>[35]</sup>

### • Antiviral Drugs

Lipid-based formulations play a crucial role in improving the bioavailability and therapeutic efficacy of antiviral drugs, especially those used in the treatment of HIV, hepatitis, and other viral infections. Many antiviral agents have poor solubility and limited absorption, which can be overcome using LBDDS such as self-emulsifying drug delivery systems (SEDDS) and nanoemulsions. These systems enhance drug solubilization and may facilitate lymphatic transport, leading to improved plasma drug concentrations and reduced dosing frequency.<sup>[36]</sup>

### • **Anti-Inflammatory Drugs**

Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents often suffer from poor aqueous solubility and gastrointestinal side effects. LBDDS can improve the solubility and absorption of these drugs while reducing gastric irritation. For example, lipid-based formulations of drugs like ibuprofen and diclofenac enhance dissolution rate and bioavailability. Additionally, topical lipid-based systems such as nanoemulsions and liposomes are used for localized delivery, minimizing systemic exposure and adverse effects.<sup>[37]</sup>

### • **Central Nervous System (CNS) Drugs**

Delivery of drugs to the central nervous system is challenging due to the presence of the blood–brain barrier (BBB). LBDDS offer promising strategies to enhance CNS drug delivery by improving drug solubility and facilitating transport across the BBB. Lipid-based nanoparticles and nanoemulsions can enhance brain uptake of drugs through mechanisms such as endocytosis and receptor-mediated transport. These systems are being explored for the treatment of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and epilepsy.<sup>[50]</sup>

## **12. Future Perspectives**

Lipid-based drug delivery systems (LBDDS) continue to evolve as a promising platform for improving the delivery of poorly water-soluble drugs. Ongoing advancements in pharmaceutical sciences, material engineering, and computational technologies are expected to further enhance their applicability and performance. The future directions of LBDDS are outlined below.<sup>[38]</sup>

### • **Development of Personalized Lipid Formulations**

With the growing emphasis on personalized medicine, there is increasing interest in designing patient-specific lipid-based formulations. Individual variability in factors such as metabolism, gastrointestinal physiology, and disease state can influence drug absorption and therapeutic response. Personalized LBDDS can be tailored based on patient-specific parameters, enabling optimized drug dosing, improved efficacy, and reduced adverse effects. Advances in pharmacogenomics and precision medicine are expected to play a key role in this area.<sup>[43]</sup>

**• Improved Stability and Scalability**

One of the major challenges in the widespread adoption of LBDDS is ensuring long-term stability and efficient large-scale production. Future research is focused on developing more stable lipid excipients, incorporating antioxidants, and optimizing formulation techniques to prevent degradation and phase separation. Additionally, advancements in manufacturing technologies, such as continuous processing and scalable nanotechnology methods, are expected to facilitate the industrial production of LBDDS with consistent quality and reproducibility.<sup>[39]</sup>

**• Integration with Nanotechnology and Artificial Intelligence**

The integration of nanotechnology with lipid-based systems has already led to the development of advanced carriers such as nanostructured lipid carriers (NLCs) and lipid-polymer hybrid nanoparticles. In the future, further innovations in nanotechnology will enable more precise control over drug release, targeting, and biodistribution. Moreover, the application of artificial intelligence (AI) and machine learning (ML) in formulation design is expected to revolutionize drug development. These technologies can predict optimal formulation parameters, reduce experimental workload, and accelerate the development of efficient and robust LBDDS.<sup>[40]</sup>

**• Regulatory Harmonization**

As LBDDS become more complex and widely used, there is a growing need for clear and harmonized regulatory guidelines. Currently, regulatory requirements for lipid-based formulations may vary across regions, creating challenges in global drug development and approval. Future efforts should focus on establishing standardized evaluation methods, safety assessment protocols, and quality control guidelines. Harmonization among regulatory agencies will facilitate smoother approval processes and promote the global adoption of LBDDS.<sup>[41]</sup>

**13. CONCLUSION**

Lipid-based drug delivery systems (LBDDS) have emerged as a highly effective and versatile approach to address the challenges associated with poorly water-soluble drugs. By enhancing solubility, improving dissolution rate, and facilitating efficient absorption, these systems significantly improve the oral bioavailability and therapeutic performance of many lipophilic drug molecules. Additionally, their ability to promote lymphatic transport and bypass hepatic first-pass metabolism further contributes to enhanced systemic drug exposure.<sup>[42]</sup>

The wide range of lipid-based formulations, including liposomes, solid lipid nanoparticles, nanostructured lipid carriers, self-emulsifying systems, and nanoemulsions, offers flexibility in formulation design and application across various therapeutic areas. Furthermore, advancements in targeted delivery and nanotechnology have expanded the potential of LBDDS in achieving site-specific drug action and reducing systemic toxicity.<sup>[51]</sup>

Despite these advantages, certain limitations such as formulation instability, potential toxicity due to high surfactant concentrations, scale-up challenges, and regulatory complexities must be carefully addressed. Continued research focusing on the development of stable lipid excipients, optimization of formulation strategies, and implementation of advanced technologies such as artificial intelligence and nanotechnology is essential to overcome these barriers.

#### 14. REFERENCE

1. (2000). Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. *European Journal of Pharmaceutical Sciences*, 11(Suppl 2): S93–S98. [https://doi.org/10.1016/S0928-0987\(00\)00167-6](https://doi.org/10.1016/S0928-0987(00)00167-6)
2. Pouton C. W., & Porter C. J. H. (2008). Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. *Advanced Drug Delivery Reviews*, 60(6): 625–637. <https://doi.org/10.1016/j.addr.2007.10.010>
3. Porter C. J. H., Trevaskis N. L., & Charman W. N. (2007). Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. *Nature Reviews Drug Discovery*, 6(3): 231–248. <https://doi.org/10.1038/nrd2197>
4. Feeney O. M., Crum M. F., McEvoy C. L., & Williams H. D. (2016). 50 years of oral lipid-based formulations: Provenance, progress and future perspectives. *Advanced Drug Delivery Reviews*, 101: 167–194. <https://doi.org/10.1016/j.addr.2016.04.007>
5. Hauss D. J. (2007). Oral lipid-based formulations: Enhancing the bioavailability of poorly water-soluble drugs. *Advanced Drug Delivery Reviews*, 59(7): 667–676. <https://doi.org/10.1016/j.addr.2007.05.006>
6. Kalepu S., & Nekkanti V. (2015). Insoluble drug delivery strategies: Review of recent advances and business prospects. *Acta Pharmaceutica Sinica B*, 5(5): 442–453. <https://doi.org/10.1016/j.apsb.2015.07.003>

7. Shahba A. A., Mohsin K., & Alanazi F. K. (2012). Novel lipid-based oral formulations for poorly water-soluble drugs. *Expert Opinion on Drug Delivery*, 9(7): 803–817. <https://doi.org/10.1517/17425247.2012.684558>
8. Mu H., & Høy C. E. (2004). The digestion of dietary triacylglycerols. *Progress in Lipid Research*, 43(4): 329–354. <https://doi.org/10.1016/j.plipres.2004.03.001>
9. Gursoy R. N., & Benita S. (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. *Biomedicine & Pharmacotherapy*, 58(3): 173–182. <https://doi.org/10.1016/j.biopha.2004.02.001>
10. Mehnert W., & Mäder K. (2001). Solid lipid nanoparticles: Production, characterization and applications. *Advanced Drug Delivery Reviews*, 47(2–3): 165–196. [https://doi.org/10.1016/S0169-409X\(01\)00105-3](https://doi.org/10.1016/S0169-409X(01)00105-3)
11. Trevaskis N. L., & Charman W. N. (2007). Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. *Nature Reviews Drug Discovery*, 6(3): 231–248. <https://doi.org/10.1038/nrd2197>
12. Pouton C. W., & Porter C. J. H. (2008). Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. *Advanced Drug Delivery Reviews*, 60(6): 625–637. <https://doi.org/10.1016/j.addr.2007.10.010>
13. Kalepu S., & Nekkanti V. (2015). Insoluble drug delivery strategies: Review of recent advances and business prospects. *Acta Pharmaceutica Sinica B*, 5(5): 442–453. <https://doi.org/10.1016/j.apsb.2015.07.003>
14. Hauss D. J. (2007). Oral lipid-based formulations: Enhancing the bioavailability of poorly water-soluble drugs. *Advanced Drug Delivery Reviews*, 59(7): 667–676. <https://doi.org/10.1016/j.addr.2007.05.006>
15. & Porter C. J. H. (2008). Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. *Advanced Drug Delivery Reviews*, 60(6): 625–637. <https://doi.org/10.1016/j.addr.2007.10.010>
16. Porter C. J. H., Trevaskis N. L., & Charman W. N. (2007). Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. *Nature Reviews Drug Discovery*, 6(3): 231–248. <https://doi.org/10.1038/nrd2197>
17. Feeney O. M., Crumb M. F., McEvoy C. L., & Williams H. D. (2016). 50 years of oral lipid-based formulations: Provenance, progress and future perspectives. *Advanced Drug Delivery Reviews*, 101: 167–194. <https://doi.org/10.1016/j.addr.2016.04.007>

18. Gursoy R. N., & Benita S. (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. *Biomedicine & Pharmacotherapy*, 58(3): 173–182. <https://doi.org/10.1016/j.biopha.2004.02.001>
19. & Mäder K. (2001). Solid lipid nanoparticles: Production, characterization and applications. *Advanced Drug Delivery Reviews*, 47(2–3): 165–196. [https://doi.org/10.1016/S0169-409X\(01\)00105-3](https://doi.org/10.1016/S0169-409X(01)00105-3)
20. Müller R. H., Radtke M., & Wissing S. A. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): Structure, properties and applications. *Advanced Drug Delivery Reviews*, 54(Suppl 1): S131–S155. [https://doi.org/10.1016/S0169-409X\(02\)00139-6](https://doi.org/10.1016/S0169-409X(02)00139-6)
21. Wissing S. A., Kayser O., & Müller R. H. (2004). Solid lipid nanoparticles for parenteral drug delivery. *Advanced Drug Delivery Reviews*, 56(9): 1257–1272. <https://doi.org/10.1016/j.addr.2003.12.002>
22. Pouton C. W. (1997). Formulation of self-emulsifying drug delivery systems. *Advanced Drug Delivery Reviews*, 25(1): 47–58. [https://doi.org/10.1016/S0169-409X\(96\)00490-5](https://doi.org/10.1016/S0169-409X(96)00490-5)
23. Gursoy R. N., & Benita S. (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. *Biomedicine & Pharmacotherapy*, 58(3): 173–182. <https://doi.org/10.1016/j.biopha.2004.02.001>
24. Shah P., Bhalodia D., & Shelat P. (2010). Nanoemulsion: A pharmaceutical review. *Systematic Reviews in Pharmacy*, 1(1): 24–32. <https://doi.org/10.4103/0975-8453.59509>
25. Solans C., Izquierdo P., Nolla J., Azemar N., & Garcia-Celma M. J. (2005). Nanoemulsions. *Current Opinion in Colloid & Interface Science*, 10(3–4): 102–110. <https://doi.org/10.1016/j.cocis.2005.06.004>
26. Patel A. R., Velikov K. P., & Van der Linden E. (2014). Colloidal delivery systems in foods: A general comparison with oral drug delivery systems. *Food Hydrocolloids*, 39: 281–291. <https://doi.org/10.1016/j.foodhyd.2014.01.022>
27. Trevaskis N. L., & Charman W. N. (2007). Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. *Nature Reviews Drug Discovery*, 6(3): 231–248. <https://doi.org/10.1038/nrd2197>
28. Pouton C. W., & Porter C. J. H. (2008). Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. *Advanced Drug Delivery Reviews*, 60(6): 625–637. <https://doi.org/10.1016/j.addr.2007.10.010>

29. Feeney O. M., Crumb M. F., McEvoy C. L., & Williams H. D. (2016). 50 years of oral lipid-based formulations: Provenance, progress and future perspectives. *Advanced Drug Delivery Reviews*, 101: 167–194. <https://doi.org/10.1016/j.addr.2016.04.007>
30. Shahba A. A., Mohsin K., & Alanazi F. K. (2012). Novel lipid-based oral formulations for poorly water-soluble drugs. *Expert Opinion on Drug Delivery*, 9(7): 803–817. <https://doi.org/10.1517/17425247.2012.684558>
31. Mu H., & Høy C. E. (2004). The digestion of dietary triacylglycerols. *Progress in Lipid Research*, 43(4): 329–354. <https://doi.org/10.1016/j.plipres.2004.03.001>
32. & Porter C. J. H. (2008). Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. *Advanced Drug Delivery Reviews*, 60(6): 625–637. <https://doi.org/10.1016/j.addr.2007.10.010>
33. Porter C. J. H., Trevaskis N. L., & Charman W. N. (2007). Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. *Nature Reviews Drug Discovery*, 6(3): 231–248. <https://doi.org/10.1038/nrd2197>
34. Feeney O. M., Crumb M. F., McEvoy C. L., & Williams H. D. (2016). 50 years of oral lipid-based formulations: Provenance, progress and future perspectives. *Advanced Drug Delivery Reviews*, 101: 167–194. <https://doi.org/10.1016/j.addr.2016.04.007>
35. Gursoy R. N., & Benita S. (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. *Biomedicine & Pharmacotherapy*, 58(3): 173–182. <https://doi.org/10.1016/j.biopha.2004.02.001>
36. Shahba A. A., Mohsin K., & Alanazi F. K. (2012). Novel lipid-based oral formulations for poorly water-soluble drugs. *Expert Opinion on Drug Delivery*, 9(7): 803–817. <https://doi.org/10.1517/17425247.2012.684558>
37. Trevaskis N. L., & Charman W. N. (2007). Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. *Nature Reviews Drug Discovery*, 6(3): 231–248. <https://doi.org/10.1038/nrd2197>
38. Pouton C. W., & Porter C. J. H. (2008). Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. *Advanced Drug Delivery Reviews*, 60(6): 625–637. <https://doi.org/10.1016/j.addr.2007.10.010>
39. Feeney O. M., Crumb M. F., McEvoy C. L., & Williams H. D. (2016). 50 years of oral lipid-based formulations: Provenance, progress and future perspectives. *Advanced Drug Delivery Reviews*, 101: 167–194. <https://doi.org/10.1016/j.addr.2016.04.007>

40. Kalepu S., & Nekkanti V. (2015). Insoluble drug delivery strategies: Review of recent advances and business prospects. *Acta Pharmaceutica Sinica B*, 5(5): 442–453. <https://doi.org/10.1016/j.apsb.2015.07.003>
41. Gursoy R. N., & Benita S. (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. *Biomedicine & Pharmacotherapy*, 58(3): 173–182. <https://doi.org/10.1016/j.biopha.2004.02.001>
42. Trevaskis N. L., & Charman W. N. (2007). Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. *Nature Reviews Drug Discovery*, 6(3): 231–248. <https://doi.org/10.1038/nrd2197>
43. Pouton C. W., & Porter C. J. H. (2008). Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. *Advanced Drug Delivery Reviews*, 60(6): 625–637. <https://doi.org/10.1016/j.addr.2007.10.010>
44. Feeney O. M., Crumb M. F., McEvoy C. L., & Williams H. D. (2016). 50 years of oral lipid-based formulations: Provenance, progress and future perspectives. *Advanced Drug Delivery Reviews*, 101: 167–194. <https://doi.org/10.1016/j.addr.2016.04.007>
45. Shahba A. A., Mohsin K., & Alanazi F. K. (2012). Novel lipid-based oral formulations for poorly water-soluble drugs. *Expert Opinion on Drug Delivery*, 9(7): 803–817. <https://doi.org/10.1517/17425247.2012.684558>
46. Gursoy R. N., & Benita S. (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. *Biomedicine & Pharmacotherapy*, 58(3): 173–182. <https://doi.org/10.1016/j.biopha.2004.02.001>
47. Crumb M. F., McEvoy C. L., & Williams H. D. (2016). 50 years of oral lipid-based formulations: Provenance, progress and future perspectives. *Advanced Drug Delivery Reviews*, 101: 167–194. <https://doi.org/10.1016/j.addr.2016.04.007>
48. Porter C. J. H., Trevaskis N. L., & Charman W. N. (2007). Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. *Nature Reviews Drug Discovery*, 6(3): 231–248. <https://doi.org/10.1038/nrd2197>
49. Mitchell M. J., Billingsley M. M., Haley R. M., Wechsler M. E., Peppas N. A., & Langer R. (2021). Engineering precision nanoparticles for drug delivery. *Nature Reviews Drug Discovery*, 20(2): 101–124. <https://doi.org/10.1038/s41573-020-0090-8>
50. Vamathevan J., Clark D., Czodrowski P., Dunham I., Ferran E., Lee G., Li B., Madabhushi A., Shah P., & Spitzer M. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery*, 18(6): 463–477. <https://doi.org/10.1038/s41573-019-0024-5>

51. U.S. Food and Drug Administration (2020). Liposome drug products: Chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation. Retrieved from <https://www.fda.gov>